Riskpilot← Back to searchSign inGet full accessBiomendex Oy
OYActiveY-tunnus 2946392-2Korkeakoulunkatu 1Manufacture of medical and dental instruments and supplies · NACE 3250Est. 2018— employeeswww.biomendex.com
Revenue 2024
EUR 42K
+74% vs 2023
EBITDA margin
-1241.7%
-1577% vs 2023
Equity ratio
10.3%
Financial strength
Net profit 2024
EUR -763K
-78% vs 2023
| Revenue | EUR 42K | +74% |
| EBITDA | EUR -518K | -1577% |
| Net profit | EUR -763K | -78% |
| Total assets | EUR 3,3M | +37% |
| Equity | EUR 338K | +314% |
| Employees | — | — |
Legal name
Biomendex Oy
Y-tunnus number
2946392-2
Legal form
Osakeyhtiö
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
16. lokakuuta 2018
Share capital
EUR 27 153
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on lääketieteellisten laitteiden, tuotteiden ja palvelujen kehitys, valmistus, markkinointi ja myynti.
Address
Korkeakoulunkatu 1
Phone
+3580405398799
Email
info@biomendex.com
Website
www.biomendex.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 7 | 12 | 24 | 42 |
| Staff expenses | −148 | −498 | −551 | −550 | −515 | −669 |
| EBITDA | −215 | −156 | −210 | −146 | −31 | −518 |
| Depreciation & amort. | −4 | −72 | −217 | −303 | −392 | −203 |
| EBIT | −219 | −228 | −427 | −450 | −423 | −721 |
| Net financials | −0 | −0 | −8 | −6 | −5 | −42 |
| Profit before tax | −219 | −228 | −435 | −456 | −428 | −763 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −219 | −228 | −435 | −456 | −428 | −763 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 1 301 | 1 622 | 2 487 | 2 178 | 2 391 | 3 284 |
| Equity | 227 | −1 | 531 | 75 | 82 | 338 |
| Long-term debt | 1 012 | 1 431 | 479 | 1 541 | 397 | 529 |
| Short-term debt | 62 | 192 | 1 476 | 562 | 1 913 | 2 417 |
| Total debt | 1 074 | 1 623 | 1 955 | 2 102 | 2 310 | 2 946 |
EBITDA margin
-1241.7%
This company
15.8%
Market median
-7959% vs market
20192024
Equity ratio
10.3%
This company
38.2%
Market median
-73% vs market
20192024
Return on equity
-225.5%
This company
18.4%
Market median
-1326% vs market
20192024
Net profit margin
-1828.5%
This company
8.1%
Market median
-22674% vs market
20192024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20192024
Debt / equity
8.71×
This company
0.62×
Market median
-1305% vs market
20192024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via PRH / YTJ · Period 2018-10-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KJ Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
HI Confidential Clerk | Confidential Clerk | 2018 | — | — |
SM Deputy auditor | Deputy auditor | 2025 | — | — |
MV Audit | Audit | 2025 | — | — |
| Audit | 2020 | — | — | |
PE Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairperson | 2025 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Biomendex Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kaarlo Johannes Paakinaho | Chief Executive Officer | 0 companies |
| Heidi Irene Hinkka | Confidential Clerk | 0 companies |
| Saila Maria Vartia | Deputy auditor | 0 companies |
| Matti Viljami Valpas | Audit | 0 companies |
| Pekka Kalevi Johannes Hiltunen | Audit | 0 companies |
| Pasi Erik Kankaanpää | Chief Executive Officer | 0 companies |
| Mikko Jukka Manninen | Board of Directors | 0 companies |
| Anna-Maria Henell | Board of Directors | 0 companies |
| Teemu Sakari Sipilä | Board of Directors | 0 companies |
| Olli Akseli Gestranius | Board of Directors | 0 companies |
| Tomi Juhani Numminen | Chairperson | 0 companies |
| Veli-Matti Ehder-Gahm | Board of Directors | 0 companies |
| Ralph Gustav Ilmari Ashorn | Board of Directors | 0 companies |
| Kaisla Elina Lahdensuo | Board of Directors | 0 companies |
| Robert Gustav Ashorn | Board of Directors | 0 companies |
| Kalevi Johannes Heinonen | Board of Directors | 0 companies |
| Mikko Juhani Latvala | Board of Directors | 0 companies |
| Antero Markku-Ilmari Salo | Board of Directors | 0 companies |
| Arto Tapio Siik | Board of Directors | 0 companies |